Clinical efficacy of anti-Mullerian hormone inspection in supporting diagnosis for climacteric disorders
نویسندگان
چکیده
The diagnosis of climacteric disorders in gynecology is performed on the basis of symptoms rather than hormonal levels. Generally, the follicle-stimulating hormone (FSH) level increases when the 17β-estradiol (E2) level decreases in menopause. However, the problem of these hormones should be determined by strict timing of sampling, and there are individual specificities of decreases of hormone levels. We considered that anti-Mullerian hormone (AMH) can be measured at any time of the menstrual cycle and that it shows ovary functional decline earlier than FSH/E2, and we examined whether AMH would possibly become a good index for climacteric disorders. The subjects were 163 healthy females and 21 patients with climacteric disorders between 20 and 59 years old. We examined AMH, FSH and E2 at the same time. It is understood that in healthy females, AMH decreases with age and a decline in ovary function occurs at a relatively early age. Patients visiting clinics for climacteric disorders often have normal-range serum FSH/E2 levels, and it is clear that these values could not serve as indices of menopause at these inspections. Upon measurement of AMH in patients with climacteric disorders, most showed less than normal range (< 14 pmol/L), suggesting a decline in ovarian function. In addition, AMH was low in females with climacteric disorders compared with those without them. In conclusion, AMH was suggested as an objective index for climacteric disorders and possibly as a new diagnostic marker.
منابع مشابه
P-75: Role of Anti-Mullerian Hormone in Prediction of Assisted Reproductive Technology Outcomes
Background: Anti-Mullerian hormone (AMH) has been suggested as a marker of ovarian reserve and predictor of ovarian response to controlled ovarian hyper stimulation. The aim of this study is to determine the role of AMH in prediction of success ART cycles in patients with normal FSH serum levels. Materials and Methods: This prospective cohort study included 80 infertile women under 4o years, wh...
متن کاملPnm-5: Anti-Mullerian Hormone in The Assessment and follow up of Cancer in Young Females
Background The impact of cancer therapy on the reproductive potential of patients is increasingly recognized because survival rates of patients have clearly improved in recent years. The study stressed the use of AMH may allow better prediction of chemotherapy-related risk to further fertility. MaterialsAndMethods A narrative review was performed within articles published at PubMed, Elsevier, S...
متن کاملThe Correlations of Anti-Mullerian Hormone, Follicle-Stimulating Hormone and Antral Follicle Count in Different Age Groups of Infertile Women
متن کامل
Relationship between Serum Levels of Anti-Mullerian Hormone, Adiponectin and Oxidative Stress Markers in Patients with Polycystic Ovary Syndrome
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. Anti-Mullerian hormone (AMH) is a valid indicator of ovarian function and is used for PCOS diagnosis. Some studies have shown that adipokines affect the synthesis of AMH, and therefore they are somehow related in function. The aim of the present study was to determine the relationshi...
متن کاملO-26: Evaluation of the Relationship betweenFollicular Fluid Anti- Mullerian Hormone Levelsand Fertilization and Embryo Quality inART Cycles
Background: To evaluate whether success of fertilization and embryo quality are more probable when follicular fluid Anti-mullerian hormone levels are higher . Materials and Methods: 62 women who underwent IVF cycle were divided into fertilized oocytes group (n=42) and non- fertilized oocytes group (n=20) . Follicular fluid Anti-mullerian hormone levels were measured in both groups. Results: Ant...
متن کامل